NYU Langone Health
Procedural, technological changes improving first-time AF ablation outcomes
Improved atrial fibrillation ablation strategies and technologies during the past decade are associated with a stepwise reduction in the rate of redo AF procedures, increased procedural volume and shortened procedure times, data show.
Inflammation levels linked to survival in acute myeloid leukemia
Severe inflammation among individuals with acute myeloid leukemia limits their bodies’ ability to kill cancerous blood cells, according to study results.
NCI-funded centers study new ways to apply telehealth across cancer care
Nearly 3 years after the COVID-19 pandemic propelled telehealth from the fringes of cancer care to the mainstream, research into the use of this technology across oncology remains limited.
Regorafenib extends survival in refractory advanced gastroesophageal cancer
Adding regorafenib to best supportive care significantly increased survival rates compared with placebo among patients with refractory advanced gastroesophageal cancer, results of the randomized, phase 3 INTEGRATE IIa trial showed.
Hassenfeld Children’s Hospital at NYU Langone names director of pediatric neuro-oncology
Jessica Clymer, MD, has been appointed director of pediatric neuro-oncology at Hassenfeld Children’s Hospital at NYU Langone.
Addressing depression may improve outcomes in psoriatic arthritis
PHILADELPHIA — Patients with psoriatic arthritis who have depression may perceive their disease differently compared with patients without depression which may make achievement of low disease activity or remission more challenging.
‘Excellent’ outcomes after ablation for AF in people with HIV
In people with HIV with atrial fibrillation, catheter ablation remains a successful therapeutic option with outcomes similar to those without HIV, data from a retrospective study show.
Breast-conserving therapy may be viable option for multiple ipsilateral breast cancer
SAN ANTONIO — Lumpectomy followed by radiation therapy resulted in low rates of local recurrence at 5 years among women with multiple ipsilateral breast cancer, according to phase 2 study results.
Data support less aggressive approach before transplant in relapsed/refractory AML
NEW ORLEANS — Skipping intensive remission-induction chemotherapy prior to allogeneic hematopoietic stem cell transplant did not impact survival outcomes among patients with relapsed/refractory acute myeloid leukemia, according to a study.
Pausing endocrine therapy for pregnancy appears safe for women with breast cancer
SAN ANTONIO — Young women with early hormone receptor-positive breast cancer who temporarily stopped endocrine therapy to attempt pregnancy experienced similar short-term recurrence risk as those who did not stop, according to study results.